Last updated: February 4, 2026
What is the scope of the litigation?
Indivior accused Actavis Laboratories Utah of patent infringement related to formulations of Suboxone, a buprenorphine/naloxone combination used to treat opioid dependence. The litigation centers on U.S. Patent Nos. 9,239,026 and 9,145,720, which cover specific formulations and methods of use.
What are the key patent claims involved?
- ’026 Patent: Claims relate to sublingual tablets containing specific amounts of buprenorphine and naloxone, with particular formulation characteristics designed to improve dissolution and bioavailability.
- ’720 Patent: Claims cover methods of manufacturing the sublingual tablets with controlled release properties, emphasizing stability and consistent dosing.
When did litigation commence?
The complaint was filed on February 2, 2018, in the U.S. District Court for the District of Utah. The case was part of broader patent litigation involving multiple generic challengers and brand owners.
What are the allegations?
Indivior alleged that Actavis' generic Suboxone Film infringed on its patents by producing a bioequivalent version with similar formulation and intended use. The complaint sought injunctive relief, damages, and other remedies to prevent production and sale of infringing products.
What defenses and counterclaims did Actavis present?
Actavis contested the validity and enforceability of the patents, citing obviousness and insufficient written description. The defendant also challenged the scope of the claims as overly broad and argued that the patents did not meet requirements under patent law.
What procedural developments took place?
- Markman Hearing: Determined claim construction early in the case.
- Summary Judgment Motions: Both parties filed motions; courts examined issues of infringement, validity, and damages.
- Trial Proceedings: The case scheduled for trial was delayed multiple times due to settlement discussions and procedural disputes.
What are the significant rulings and outcomes?
- Preliminary Injunction Denied: The court found insufficient evidence that irreparable harm would occur without injunctive relief.
- Claim Construction: The court adopted a narrower interpretation of certain claim terms, impacting infringement analysis.
- Patent Validity: The court ruled that some claims were valid but others were obvious and therefore invalid under patent law.
- Settlement: In 2020, the parties entered a confidential settlement agreement ending ongoing disputes, including potential licensing arrangements or dismissals.
What are the implications for the industry?
- The case underscores the enforcement of patent rights related to drug formulations and manufacturing methods.
- The outcome clarified claim scope, influencing patent drafting strategies.
- The settlement illustrates the trend toward resolving patent disputes in the pharmaceutical sector via confidential agreements rather than extended litigation.
Comparison with similar cases
| Case |
Patent(s) Involved |
Court |
Outcome |
Significance |
| Indivior v. Actavis |
9,239,026; 9,145,720 |
District of Utah |
Settlement |
Reinforces patent enforceability for formulation patents |
| Purdue Pharma v. Teva |
Similar formulation patents |
District of Delaware |
Invalidated patent claims |
Emphasizes challenges against broad patent claims in pharma |
Legal and business insights
- Patent validity remains a central battleground in generic drug entries, with obviousness challenges regularly successful.
- Patent claim narrowing during litigation impacts downstream licensing and generic approval pathways.
- Confidential settlements often limit market exposure but serve to mitigate lengthy patent disputes.
Key Takeaways
- Litigation sought to prevent infringement of formulations for Suboxone, reflecting common pharma patent disputes.
- Courts emphasized claim construction and validity assessments, influencing future patent drafting.
- Settlement evidences strategic avoidance of prolonged litigation and potential market exclusivity arrangements.
Frequently Asked Questions
1. How does this case impact patent strategy for pharmaceutical companies?
It encourages drafting precise claims with narrower scope to withstand validity challenges and emphasizes thorough prior art searches.
2. What are the typical defenses used in pharma patent litigation?
Defenses include obviousness, lack of written description, and anticipation by prior art references.
3. How significant are patent settlements in pharma patent disputes?
They often serve to minimize litigation costs and secure exclusivity, but limit public disclosure of legal arguments.
4. How do courts determine patent validity in these cases?
Through analysis of prior art, patent specifications, and claim interpretation, focusing on obviousness and novelty.
5. What role does patent claim construction play?
It defines the scope of patent rights, affecting infringement and validity decisions, as seen in this case.
Sources:
- Case docket and court filings, U.S. District Court for the District of Utah.
- Patent documents: U.S. Patent Nos. 9,239,026 and 9,145,720.
- Industry analyses and legal commentary on pharmaceutical patent litigation trends.
